| scholarly article | Q13442814 |
| P50 | author | Dimas Covas | Q37366804 |
| Daniel Guariz Pinheiro | Q42877178 | ||
| Eduardo Antonio Donadi | Q56449381 | ||
| Rodrigo A Panepucci | Q56616469 | ||
| Doralina Guimarães Brum Souza | Q62743417 | ||
| G L V de Oliveira | Q83942515 | ||
| P2093 | author name string | Belinda P Simões | |
| Kelen C R Malmegrim | |||
| Maria C de Oliveira | |||
| Patrícia V B Palma | |||
| Amanda M Colombini | |||
| Kalil W A de Lima | |||
| P2860 | cites work | Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 |
| Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction | Q25938986 | ||
| Mesenchymal stem cell transplantation in multiple sclerosis | Q26999783 | ||
| Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources | Q27860739 | ||
| A molecular trio in relapse and remission in multiple sclerosis | Q28245076 | ||
| Mesenchymal stem cells in health and disease | Q29614296 | ||
| Autoimmune T cell responses in the central nervous system | Q33620003 | ||
| Developing therapeutics for the treatment of multiple sclerosis | Q33946995 | ||
| Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. | Q34007524 | ||
| Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis | Q34120467 | ||
| Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study | Q34132522 | ||
| New diagnostic criteria for multiple sclerosis: guidelines for research protocols | Q34271601 | ||
| Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis | Q34564111 | ||
| The promise of stem cell and regenerative therapies for multiple sclerosis | Q34781833 | ||
| Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study | Q35757641 | ||
| Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines | Q35861182 | ||
| Cell therapy for autoimmune diseases | Q35868954 | ||
| Hepatocyte growth factor mediates mesenchymal stem cell–induced recovery in multiple sclerosis models. | Q36188460 | ||
| Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. | Q36402704 | ||
| Hematopoietic stem cell transplantation for autoimmune diseases: what have we learned? | Q37074892 | ||
| Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. | Q37241672 | ||
| Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. | Q37253314 | ||
| Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? | Q37811173 | ||
| Exploring the role of soluble factors associated with immune regulatory properties of mesenchymal stem cells | Q37924625 | ||
| The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms | Q37978701 | ||
| Immunosuppressive properties of mesenchymal stem cells: advances and applications. | Q38003737 | ||
| Worldwide status of clinical experimentation with stem cells in neurologic diseases | Q38005098 | ||
| Multipotent mesenchymal stromal cells and the innate immune system | Q38005275 | ||
| Will the real multiple sclerosis please stand up? | Q38020092 | ||
| Mesenchymal stromal cells: a key player in 'innate tolerance'? | Q38026931 | ||
| Mechanisms of mesenchymal stromal cell immunomodulation | Q38054535 | ||
| Mesenchymal stem cells as treatment for MS - progress to date. | Q38057682 | ||
| Stem cell applications in regenerative medicine for neurological disorders | Q38057870 | ||
| Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. | Q40241704 | ||
| Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis. | Q44621693 | ||
| In vitro assessment of mesenchymal stem cells immunosuppressive potential in multiple sclerosis patients | Q45011534 | ||
| Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. | Q45834735 | ||
| Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. | Q45936271 | ||
| Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms | Q46390299 | ||
| Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice | Q46499204 | ||
| Distinct immunomodulatory and migratory mechanisms underpin the therapeutic potential of human mesenchymal stem cells in autoimmune demyelination. | Q46636028 | ||
| Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis | Q48227850 | ||
| Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice | Q48497239 | ||
| Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. | Q50632074 | ||
| Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. | Q50767537 | ||
| Mesenchymal stem cells for graft-versus-host disease: close encounters with T cells. | Q53476120 | ||
| Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. | Q53523180 | ||
| P433 | issue | 2 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 151-165 | |
| P577 | publication date | 2013-11-20 | |
| P1433 | published in | Cell Transplantation | Q15761863 |
| P1476 | title | Bone marrow mesenchymal stromal cells isolated from multiple sclerosis patients have distinct gene expression profile and decreased suppressive function compared with healthy counterparts. | |
| P478 | volume | 24 |
| Q35710705 | A Methodology for the Development of RESTful Semantic Web Services for Gene Expression Analysis |
| Q41571231 | Adipose stem cells from chronic pancreatitis patients improve mouse and human islet survival and function |
| Q39180886 | Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial |
| Q48029148 | CNS disease diminishes the therapeutic functionality of bone marrow mesenchymal stem cells. |
| Q39233323 | Cell Therapy for Multiple Sclerosis |
| Q47885870 | Cell-based therapeutic strategies for multiple sclerosis |
| Q48503911 | Increased motility of mesenchymal stem cells is correlated with inhibition of stimulated peripheral blood mononuclear cells in vitro |
| Q51692400 | Influence of the intensity and loading time of direct current electric field on the directional migration of rat bone marrow mesenchymal stem cells. |
| Q41196008 | Multipotent mesenchymal stromal cells from patients with newly diagnosed type 1 diabetes mellitus exhibit preserved in vitro and in vivo immunomodulatory properties. |
| Q38734508 | Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis |
| Q47363542 | Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro |
| Q49343380 | Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis |
| Q91761207 | Short and Long Term Clinical and Immunologic Follow up after Bone Marrow Mesenchymal Stromal Cell Therapy in Progressive Multiple Sclerosis-A Phase I Study |
| Q54988530 | Transcriptional Profiling of Mesenchymal Stem Cells Identifies Distinct Neuroimmune Pathways Altered by CNS Disease. |
| Q37089931 | Transcriptional profiling reveals intrinsic mRNA alterations in multipotent mesenchymal stromal cells isolated from bone marrow of newly-diagnosed type 1 diabetes patients |
Search more.